Back

Newron expands ENIGMA-TRS 2 enrollment outside U.S. as FDA hold continues

Verifying
  • Newron expands ENIGMA-TRS 2 sites and enrollment outside the United States.
  • Approximately 80 patients have entered screening for the study so far.
  • FDA’s U.S. enrollment hold followed a participant death reported on April 29, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.